Evaluation of sodium‐glucose cotransporter 2 inhibitors for renal prognosis and mortality in diabetes patients with heart failure on diuretics
Abstract Previous studies about renal protection of sodium‐glucose cotransporter 2 inhibitors (SGLT2i) in type 2 diabetes mellitus (T2DM) patients with heart failure (HF) on diuretics were still limited. The goal of the study is to survey the efficacy of SGLT2i to reduce all‐cause mortality and rena...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-04-01
|
| Series: | Kaohsiung Journal of Medical Sciences |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/kjm2.12635 |
| _version_ | 1827970138722271232 |
|---|---|
| author | Yi‐Fang Weng Chung‐Yu Chen Shang‐Jyh Hwang Yaw‐Bin Huang |
| author_facet | Yi‐Fang Weng Chung‐Yu Chen Shang‐Jyh Hwang Yaw‐Bin Huang |
| author_sort | Yi‐Fang Weng |
| collection | DOAJ |
| description | Abstract Previous studies about renal protection of sodium‐glucose cotransporter 2 inhibitors (SGLT2i) in type 2 diabetes mellitus (T2DM) patients with heart failure (HF) on diuretics were still limited. The goal of the study is to survey the efficacy of SGLT2i to reduce all‐cause mortality and renal impairments in patients with T2DM and HF using diuretics. The retrospective cohort study was analyzed from Kaohsiung Medical University Hospital Research Database (KMUHRD) in Taiwan. Adults with T2DM and HF using any diuretics at least 28 days during 2016–2018 were enrolled and then divided into the SGLT2i group and the non‐SGLT2i group. Propensity score matching was used to balance baseline characteristics between the two groups. The primary outcome was all‐cause mortality. Secondary outcomes contained dialysis occurrence, renal progression, and acute kidney injury (AKI). After 1:1 matching, there were 183 patients in each group respectively. When compared with the non‐SGLT2i group, the SGLT2i group had significantly lower all‐cause mortality (hazard ratios [HR]: 0.49, 95% CI 0.29–0.83, p = 0.008) and reduction of renal progression (HR: 0.30, 95% CI 0.12–0.75, p = 0.010). SGLT2i showed the trend to decrease dialysis occurrence (HR: 0.83, 95% CI 0.20–3.47, p = 0.797) and an increase in AKI (HR: 1.38, 95% CI 0.67–2.87, p = 0.383) but without significance. SGLT2 inhibitors were associated with reduced all‐cause mortality and less renal progression with significance in T2DM patients with HF on diuretics. |
| first_indexed | 2024-04-09T18:48:33Z |
| format | Article |
| id | doaj.art-4186efc6b3404aa98c099499fb394b18 |
| institution | Directory Open Access Journal |
| issn | 1607-551X 2410-8650 |
| language | English |
| last_indexed | 2024-04-09T18:48:33Z |
| publishDate | 2023-04-01 |
| publisher | Wiley |
| record_format | Article |
| series | Kaohsiung Journal of Medical Sciences |
| spelling | doaj.art-4186efc6b3404aa98c099499fb394b182023-04-10T06:31:28ZengWileyKaohsiung Journal of Medical Sciences1607-551X2410-86502023-04-0139441642510.1002/kjm2.12635Evaluation of sodium‐glucose cotransporter 2 inhibitors for renal prognosis and mortality in diabetes patients with heart failure on diureticsYi‐Fang Weng0Chung‐Yu Chen1Shang‐Jyh Hwang2Yaw‐Bin Huang3Master Degree Program in Clinical Pharmacy School of Pharmacy, College of Pharmacy, Kaohsiung Medical University Kaohsiung TaiwanMaster Degree Program in Clinical Pharmacy School of Pharmacy, College of Pharmacy, Kaohsiung Medical University Kaohsiung TaiwanSchool of Medicine College of Medicine, Kaohsiung Medical University Kaohsiung TaiwanDepartment of Pharmacy Kaohsiung Medical University Hospital Kaohsiung TaiwanAbstract Previous studies about renal protection of sodium‐glucose cotransporter 2 inhibitors (SGLT2i) in type 2 diabetes mellitus (T2DM) patients with heart failure (HF) on diuretics were still limited. The goal of the study is to survey the efficacy of SGLT2i to reduce all‐cause mortality and renal impairments in patients with T2DM and HF using diuretics. The retrospective cohort study was analyzed from Kaohsiung Medical University Hospital Research Database (KMUHRD) in Taiwan. Adults with T2DM and HF using any diuretics at least 28 days during 2016–2018 were enrolled and then divided into the SGLT2i group and the non‐SGLT2i group. Propensity score matching was used to balance baseline characteristics between the two groups. The primary outcome was all‐cause mortality. Secondary outcomes contained dialysis occurrence, renal progression, and acute kidney injury (AKI). After 1:1 matching, there were 183 patients in each group respectively. When compared with the non‐SGLT2i group, the SGLT2i group had significantly lower all‐cause mortality (hazard ratios [HR]: 0.49, 95% CI 0.29–0.83, p = 0.008) and reduction of renal progression (HR: 0.30, 95% CI 0.12–0.75, p = 0.010). SGLT2i showed the trend to decrease dialysis occurrence (HR: 0.83, 95% CI 0.20–3.47, p = 0.797) and an increase in AKI (HR: 1.38, 95% CI 0.67–2.87, p = 0.383) but without significance. SGLT2 inhibitors were associated with reduced all‐cause mortality and less renal progression with significance in T2DM patients with HF on diuretics.https://doi.org/10.1002/kjm2.12635diureticsheart failuremortalitySGLT2 inhibitorstype 2 diabetes mellitus |
| spellingShingle | Yi‐Fang Weng Chung‐Yu Chen Shang‐Jyh Hwang Yaw‐Bin Huang Evaluation of sodium‐glucose cotransporter 2 inhibitors for renal prognosis and mortality in diabetes patients with heart failure on diuretics Kaohsiung Journal of Medical Sciences diuretics heart failure mortality SGLT2 inhibitors type 2 diabetes mellitus |
| title | Evaluation of sodium‐glucose cotransporter 2 inhibitors for renal prognosis and mortality in diabetes patients with heart failure on diuretics |
| title_full | Evaluation of sodium‐glucose cotransporter 2 inhibitors for renal prognosis and mortality in diabetes patients with heart failure on diuretics |
| title_fullStr | Evaluation of sodium‐glucose cotransporter 2 inhibitors for renal prognosis and mortality in diabetes patients with heart failure on diuretics |
| title_full_unstemmed | Evaluation of sodium‐glucose cotransporter 2 inhibitors for renal prognosis and mortality in diabetes patients with heart failure on diuretics |
| title_short | Evaluation of sodium‐glucose cotransporter 2 inhibitors for renal prognosis and mortality in diabetes patients with heart failure on diuretics |
| title_sort | evaluation of sodium glucose cotransporter 2 inhibitors for renal prognosis and mortality in diabetes patients with heart failure on diuretics |
| topic | diuretics heart failure mortality SGLT2 inhibitors type 2 diabetes mellitus |
| url | https://doi.org/10.1002/kjm2.12635 |
| work_keys_str_mv | AT yifangweng evaluationofsodiumglucosecotransporter2inhibitorsforrenalprognosisandmortalityindiabetespatientswithheartfailureondiuretics AT chungyuchen evaluationofsodiumglucosecotransporter2inhibitorsforrenalprognosisandmortalityindiabetespatientswithheartfailureondiuretics AT shangjyhhwang evaluationofsodiumglucosecotransporter2inhibitorsforrenalprognosisandmortalityindiabetespatientswithheartfailureondiuretics AT yawbinhuang evaluationofsodiumglucosecotransporter2inhibitorsforrenalprognosisandmortalityindiabetespatientswithheartfailureondiuretics |